MindMed’s collaborators at University Hospital Basel studied the effect of two high doses of LSD (200μg) on patients with anxiety disorders.
They found that 65% of subjects had significant reductions in anxiety scores for 16 weeks after the treatments.
Like many other studies have found, mystical experiences were significantly correlated with long-term therapeutic benefits.
At least 17 activists were arrested for protesting at the DEA headquarters. The purpose of the protest was to raise awareness about the DEA’s obstruction of access to psilocybin therapy, which should be legal for terminally ill patients through the Right to Try (RTT) laws.
“There is urgent need for the DEA to accommodate RTT and enable access (to psilocybin). This demonstration shines the bright light of public concern and outrage on this agency’s conduct,” says Kathryn Tucker, the attorney behind the litigation.
Leveraging over 20 years of psychedelic research, Beckley Foundation is launching a psilocybin-focused holistic wellbeing company called Beckley Retreats.
Starting this September, Beckley Retreats will offer a self-development program that includes:
Led by certified psychotherapists and doctors, the retreat combines Indigenous wisdom with modern science to create an unparalleled experience.
Learn more and reserve your spot here.
Psycheceutical Inc., a subsidiary of Psycheceutical Bioscience (BWVI), announced that OG Shark Tank investor Kevin Harrington is joining the company as an investor and strategic advisor.
FSD Pharma (HUGE) sold its assets related to cannabis processing to focus on biotech. The C$16.4M in proceeds give the company enough capital to support operations through 2025.
PharmAla Biotech (MDMA) signed a distribution agreement with CCrest Laboratories, making its MDMA available to both international and domestic customers.
MAPS announced that its Phase 3 MDMA trial for PTSD is now fully enrolled at 13 sites across the United States and Israel.
The organization took equity initiatives to ensure that BIPOC and LGBTQ+ individuals are represented in the study, as these individuals are more likely to have PTSD (yet less likely to be diagnosed or have reasonable access to treatment).
COMPASS Pathways (CMPS) is funding a psilocybin study to better understand the brain science of neurodiversity.
Using brain imaging and behavioural tasks, researchers will investigate how psilocybin affects the serotonin brain networks in autistic adults compared to non-autistic adults.
The goal is to understand the unique brain mechanisms associated with autism to provide “better tailored choices” to autistic people.
CMPS shares spiked 11% yesterday after the company announced Q1 financial results, including $21.2M net loss and $243.7M in cash.
The results from Cybin and Kernel’s brain imaging study are in!
The findings suggest that a single dose of ketamine has a lasting effect on the way information flows through the brain.
Subjects’ brain activity patterns were relatively stable for 5 days leading up to the ketamine session.
After a low dose of ketamine, there were significant changes in functional connectivity lasting at least 5 days.
Wesana Health (WESA) is considering selling all assets related to client care (like its network of ketamine clinics and mental health software) to focus solely on drug development.
